Shin Hak-Cheol, LG Chem CEO (Jean Chung/Bloomberg via Getty Images)
Korean buyer jumps into M&A game with $566M bid for Aveo Oncology
More than 12 years ago, Aveo Oncology vaulted onto Nasdaq with an IPO pitch centered on its lead cancer drug, tivozanib. It took almost a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
